The study of serum FAM172A predicting the risk of macrovascular complications in Type 2 diabetes mellitus

Status

Active, not recruiting

Phases

Early Phase 1

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR2100043521

Enrollment

Unknown

Registered

2021-02-21

Start date

2022-01-01

Completion date

Unknown

Last updated

2021-06-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Macrovascular complications in Type 2 diabetes mellitus

Interventions

normal person:no

type 2 diabetes without macrovascular diseases:no

type 2 diabetes with macrovascular diseases:no

type 2 diabetes:no

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Normal persons: 1. Those who sign the informed consent; 2. Age: 18-75; 3. Liver and kidney function is normal. Patients with type 2 diabetes: 1. Those who signed the informed consent; 2. Age: above 18 years old; 3. Fasting blood glucose >= 7.0 mmol/L and/or 2 hours postprandial blood glucose >= 11.1 mmol/L.

Exclusion criteria

Exclusion criteria: Normal persons: 1. Previous history of diabetes; 2. Have a history of serious organic diseases such as heart failure, liver and kidney failure; Previous thyroid cancer and other neoplastic diseases; Previous history of stroke, myocardial infarction and other cardiovascular and cerebrovascular diseases. Patients with type 2 diabetes: 1. Unclear classification of diabetes; 2. Have a history of serious organic diseases such as heart failure, liver and kidney failure; 3. Previous thyroid cancer and other neoplastic diseases.

Design outcomes

Primary

Measure	Time frame
serum FAM172A;	—

Countries

China

Contacts

Public ContactLi Meifang

Shanghai Sixth People's Hospital

15821955054@126.com+86 18930170426

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026